China Pharma makes generic and branded injectables, tablets, and capsules for Chinese hospitals and pharmacies, covering everything from stroke recovery to sore throats. Think of a local drugstore shelf stocked with dozens of cheap, familiar medicines.
Revenue is tiny and shrinking, with gross margin at 8.81% and net margin deeply negative at -153.76%, meaning every sale loses money. There's no recurring income stream, just one-off product sales that don't cover costs.
No visible protection: any Chinese generic maker like Sinopharm or Harbin Pharmaceutical can copy these standard drugs, and the company's negative margins show it has no pricing power or scale advantage.
Key events, in time order
Company responds to extreme price swings and announces share repurchase plan
Company officially prices offering to raise $5 million
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
